Table 3.
The univariable and multivariable analysis of the logistic regression in diagnosing MF-ICC in the training sets.
| Variables | Univariable factors | P value | Multivariable factors | P value |
|---|---|---|---|---|
| Clinical features | OR (95%CI) | OR (95%CI) | ||
| AFP (≥20ng/mL) | 2.31(0.75-7.07) | 0.841 | ||
| CA19-9(≥36U/mL) | 3.70(2.14-6.40) | <0.001 | 2.81(1.06-7.44) | 0.037 |
| CEA(≥5ng/mL) | 0.19(0.11-0.33) | <0.001 | 0.05(0.02-0.16) | <0.001 |
| CA125 (≥35ng/mL) | 7.42(3.12-17.62) | <0.001 | 10.21 (2.54-40.99) | 0.001 |
| Lesion size (≥5cm) | 9.53(5.10-17.80) | <0.001 | 13.99(4.82-40.68) | <0.001 |
| Lesion number(single) | 2.28(1.35-3.85) | 0.002 | 5.58(2.09-14.91) | 0.001 |
| Abnormal lymph node | 4.58(1.98-10.59) | 0.018 | ||
| Bile duct dilation | 5.23(1.38-19.82) | 0.015 | ||
| Echogenicity | ||||
| hypo | reference | reference | reference | |
| iso | 0.23(0.07-0.98) | 0.048 | 0.15(0.018-1.34) | 0.092 |
| hyper | 0.20(0.10-0.41) | <0.001 | 0.23(0.07-0.65) | 0.007 |
| Irregular Shape | 2.56(1.44-4.54) | 0.001 | 1.91(0.75-4.88) | 0.173 |
| Rim APHE | 0.41(0.25-0.68) | <0.001 | 0.36(0.14- 0.92) | 0.034 |
| Unclear boundary of intratumor non-enhanced area | ||||
| yes | 2.80(1.27-6.17) | 0.01 | ||
| no | reference | |||
| Tumor necrosis | 2.79(1.57-4.95) | <0.001 | 3.78(1.37-10.38) | 0.01 |
| Necrosis area | ||||
| absence | reference | reference | ||
| < 50% area | 3.10(1.33-7.23) | 0.009 | ||
| ≥50% area | 2.61(1.32-5.18) | 0.006 | ||
MF-ICC, mass-forming intrahepatic cholangiocarcinoma; OR, odds ratio; CI, confidence interval. AFP, alpha fetoprotein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; APHE, arterial phase hyper- enhancement.